scholarly journals Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer ◽  
2020 ◽  
Vol 126 (18) ◽  
pp. 4156-4167 ◽  
Author(s):  
Robert J. Motzer ◽  
Bernard Escudier ◽  
Saby George ◽  
Hans J. Hammers ◽  
Sandhya Srinivas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Long Term Follow Up

scholarly journals Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

2016 ◽  
Vol 17 (7) ◽  
pp. 917-927 ◽  
Author(s):  
Toni K Choueiri ◽  
Bernard Escudier ◽  
Thomas Powles ◽  
Nizar M Tannir ◽  
Paul N Mainwaring ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase

scholarly journals Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

2018 ◽  
Vol 118 (9) ◽  
pp. 1176-1178 ◽  
Author(s):  
Robert J. Motzer ◽  
Bernard Escudier ◽  
Thomas Powles ◽  
Christian Scheffold ◽  
Toni K. Choueiri
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Long Term Follow Up

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

2019 ◽  
Author(s):  
Brian Rini ◽  
Sumanta K. Pal ◽  
Bernard J. Escudier ◽  
Michael B. Atkins ◽  
Thomas E. Hutson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study

scholarly journals Succinate Dehydrogenase–Deficient Renal Cell Carcinoma

2018 ◽  
Vol 143 (5) ◽  
pp. 643-647 ◽  
Author(s):  
Tsung-Heng Tsai ◽  
Wen-Ying Lee
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Succinate Dehydrogenase ◽  
Renal Cell ◽  
World Health ◽  
Low Grade ◽  
Long Term Follow Up ◽  
Health Organization

Succinate dehydrogenase (SDH)–deficient renal cell carcinoma is a recently recognized distinct subtype of renal cell carcinoma in the 2016 World Health Organization classification. It is associated with SDH gene germline mutations, which also cause paraganglioma/pheochromocytoma, gastrointestinal stromal tumor, and pituitary adenoma. The tumor most commonly presents in young adulthood. The tumors are arranged in solid nests or in tubules and frequently show cystic change. The tumors are composed of cuboidal to oval cells with round nuclei, dispersed chromatin, and inconspicuous nucleoli. The cytoplasm is eosinophilic or flocculent but not truly oncocytic. The most distinctive histologic feature is the presence of cytoplasmic vacuoles or inclusions. Loss of SDH subunit B immunostaining is needed for a definite diagnosis. The prognosis is good for low-grade tumors but worse for tumors with high-grade nuclei, sarcomatoid change, or coagulative necrosis. Long-term follow-up is indicated.

Sign in / Sign up

Export Citation Format

Share Document